Patent: 10,377,832
✉ Email this page to a colleague
Summary for Patent: 10,377,832
| Title: | Modified glycoproteins |
| Abstract: | Modified glycoproteins, and methods of making and using such modified glycoproteins, are described. |
| Inventor(s): | Washburn; Nathaniel (Littleton, MA), Meador, III; James (Framingham, MA), Bosques; Carlos J. (Arlington, MA), Bulik; Dorota A. (Malden, MA), Bhatnagar; Naveen (Framingham, MA), Brown; Julia (Somerville, MA), Markowitz; Lynn (Waltham, MA), Prabbhakar; Sathya (Boxborough, MA) |
| Assignee: | Momenta Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 15/497,057 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,377,832
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 22-Dec-94 | ⤷ Start Trial | 2037-04-25 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 26-Nov-97 | ⤷ Start Trial | 2037-04-25 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 10-Dec-97 | ⤷ Start Trial | 2037-04-25 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 12-May-98 | ⤷ Start Trial | 2037-04-25 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 2-Jan-03 | ⤷ Start Trial | 2037-04-25 |
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 19-Jun-98 | ⤷ Start Trial | 2037-04-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
